Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + ephedrine is a combination drug consisting of lidocaine, an amide-type local anesthetic, and ephedrine, a sympathomimetic agent. Lidocaine works by blocking voltage-gated sodium channels in neuronal cell membranes, thereby inhibiting nerve impulse conduction and producing local or regional anesthesia. Ephedrine acts primarily as an agonist at alpha-1, beta-1, and beta-2 adrenergic receptors; it increases blood pressure through vasoconstriction (alpha-1), enhances cardiac output (beta-1), and causes bronchodilation (beta-2). The combination may be used to provide local anesthesia with the added benefit of counteracting hypotension or prolonging anesthetic effect via vasoconstriction. While combinations of lidocaine with other sympathomimetics like epinephrine are common in clinical practice for dental or surgical anesthesia[2][3][4], the specific pairing with ephedrine is less commonly documented but may be considered for its pressor effects during procedures where hypotension is a concern[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + ephedrine.